Skip to main content
SpringerLink
Log in

Current Concepts in Diabetic Gastroparesis

  • Therapy in Practice
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Diabetic gastroparesis is a common and debilitating condition affecting millions of patients with diabetes mellitus worldwide. Although gastroparesis in diabetes has been known clinically for more than 50 years, treatment options remain very limited. Until recently, the scientific literature has offered few clues regarding the precise aetiology of gastric dysfunction in diabetes.

Up to 50% of patients with diabetes may experience postprandial abdominal pain, nausea, vomiting and bloating secondary to gastric dysfunction. There is no clear association between length of disease and the onset of delayed gastric emptying. Gastroparesis affects both type 1 (insulin dependent) and type 2 (non-insulin dependent) forms of diabetes. Diagnosis requires identifying the proper symptom complex, while excluding other entities (peptic ulcer disease, rheumatological diseases, medication effects). The diagnosis of gastroparesis may be confirmed by demonstrating gastric emptying delay during a 4-hour scintigraphic study. Treatment options are limited and rely on dietary modifications, judicious use of available pharmacological agents, and occasionally surgical or endoscopic placement of gastrostomies or jejunostomies. Gastric pacing offers promise for patients with medically refractory gastroparesis but awaits further investigation.

Current pharmacological agents for treating gastroparesis include metoclopramide, erythromycin, cisapride (only available via a company-sponsored programme) and domperidone (not US FDA approved). All of these drugs act as promotility agents that increase the number or the intensity of gastric contractions. These medications are not uniformly effective and all have adverse effects that limit their use. Cisapride has been removed from the open market as a result of over 200 reported cases of cardiac toxicity attributed to its use. Unfortunately, there is a paucity of clinical studies that clearly define the efficacy of these agents in diabetic gastroparesis and there are no studies that compare these drugs to each other.

The molecular pathophysiology of diabetic gastroparesis is unknown, limiting the development of rational therapies. New studies, primarily in animals, point to a defect in the enteric nervous system as a major molecular cause of abnormal gastric motility in diabetes. This defect is characterised by a loss of nitric oxide signals from nerves to muscles in the gut resulting in delayed gastric emptying. Novel therapies designed to augment nitric oxide signalling are being studied.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Table I
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Nilsson PH. Diabetic gastroparesis: a review. J Diabetes Complications 1996; 10(2): 113–22

    Article  PubMed  CAS  Google Scholar 

  2. Koch KL. Diabetic gastropathy: gastric neuromuscular dysfunction in diabetes mellitus. A review of symptoms, pathophysiology, and treatment. Dig Dis Sci 1999; 44(6): 1061–75

    CAS  Google Scholar 

  3. Hornbuckle K, Barnett JL. The diagnosis and work-up of the patient with gastroparesis. J Clin Gastroenterol 2000; 30(2): 117–24

    Article  PubMed  CAS  Google Scholar 

  4. McCallum RW, George SJ. Gastric dysmotility and gastroparesis. Curr Treat Options Gastroenterol 2001; 4(2): 179–91

    Article  PubMed  Google Scholar 

  5. Bityutskiy LP, Soykan I, McCallum RW. Viral gastroparesis: a subgroup of idiopathic gastroparesis. Clinical characteristics and long-term outcomes. Am J Gastroenterol 1997; 92(9): 1501–4

    CAS  Google Scholar 

  6. Rundles RW. Diabetic neuropathy: general review with report of 125 cases. Medicine (Baltimore) 1945; 24: 111–60

    Article  Google Scholar 

  7. Kassander P. Asymptomatic gastric retention in diabetics (gastroparesis diabeticorum). Ann Intern Med 1958; 48: 797–812

    PubMed  CAS  Google Scholar 

  8. Horowitz M, Edelbroek M, Fraser R, et al. Disordered gastric motor function in diabetes mellitus: recent insights into prevalence, pathophysiology, clinical relevance, and treatment. Scand J Gastroenterol 1991; 26(7): 673–84

    Article  PubMed  CAS  Google Scholar 

  9. Janatuinen E, Pikkarainen P, Laakso M, et al. Gastrointestinal symptoms in middle-aged diabetic patients. Scand J Gastroenterol 1993; 28(5): 427–32

    Article  PubMed  CAS  Google Scholar 

  10. Maleki D, Locke GR, Camilleri M, et al. Gastrointestinal tract symptoms among persons with diabetes mellitus in the community. Arch Intern Med 2000; 160(18): 2808–16

    Article  PubMed  CAS  Google Scholar 

  11. Bytzer P, Talley NJ, Leemon M, et al. Prevalence of gastrointestinal symptoms associated with diabetes mellitus: a population-based survey of 15,000 adults. Arch Intern Med 2001; 161(16): 1989–96

    Article  PubMed  CAS  Google Scholar 

  12. Clouse RE, Lustman PJ. Gastrointestinal symptoms in diabetic patients: lack of association with neuropathy. Am J Gastroenterol 1989; 84(8): 868–72

    PubMed  CAS  Google Scholar 

  13. Malagelada JR. Diabetic gastroparesis. Semin Gastrointest Dis 1995; 6(4): 181–6

    PubMed  CAS  Google Scholar 

  14. Horowitz M, Maddox AF, Wishart JM, et al. Relationships between oesophageal transit and solid and liquid gastric emptying in diabetes mellitus. Eur J Nucl Med 1991; 18(4): 229–34

    Article  PubMed  CAS  Google Scholar 

  15. Loo FD, Palmer DW, Soergel KH, et al. Gastric emptying in patients with diabetes mellitus. Gastroenterology 1984; 86(3): 485–94

    PubMed  CAS  Google Scholar 

  16. Bytzer PM, Hammer J, Talley NJ, et al. Gastrointestinal symptoms in diabetes mellitus are associated with diabetic complications but not with current glycemic control [abstract]. Gastroenterology 2000; 118: A2546

    Google Scholar 

  17. Horowitz M, Harding PE, Maddox AF, et al. Gastric and oesophageal emptying in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1989; 32(3): 151–9

    Article  PubMed  CAS  Google Scholar 

  18. Iber FL, Parveen S, Vandrunen M, et al. Relation of symptoms to impaired stomach, small bowel, and colon motility in longstanding diabetes. Dig Dis Sci 1993; 38(1): 45–50

    Article  PubMed  CAS  Google Scholar 

  19. Kong MF, Horowitz M, Jones KL, et al. Natural history of diabetic gastroparesis. Diabetes Care 1999; 22(3): 503–7

    Article  PubMed  CAS  Google Scholar 

  20. Undeland KA, Hausken T, Gilja OH, et al. Gastric meal accommodation studied by ultrasound in diabetes: relation to vagal tone. Scand J Gastroenterol 1998; 33(3): 236–41

    Article  PubMed  CAS  Google Scholar 

  21. Urbain JL, Vekemans MC, Bouillon R, et al. Characterization of gastric antral motility disturbances in diabetes using a scintigraphic technique. J Nucl Med 1993; 34(4): 576–81

    PubMed  CAS  Google Scholar 

  22. Jebbink HJ, Bravenboer B, Akkermans LM, et al. Relationships between dyspeptic symptoms and gastrointestinal motility in patients with type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1993; 36(10): 948–54

    Article  PubMed  CAS  Google Scholar 

  23. Samsom M, Jebbink RJ, Akkermans LM, et al. Abnormalities of antroduodenal motility in type I diabetes. Diabetes Care 1996; 19(1): 21–7

    Article  PubMed  CAS  Google Scholar 

  24. Camilleri M, Malagelada JR. Abnormal intestinal motility in diabetics with the gastroparesis syndrome. Eur J Clin Invest 1984; 14(6): 420–7

    Article  PubMed  CAS  Google Scholar 

  25. Mearin F, Camilleri M, Malagelada JR. Pyloric dysfunction in diabetics with recurrent nausea and vomiting. Gastroenterology 1986; 90(6): 1919–25

    PubMed  CAS  Google Scholar 

  26. Huang PL, Dawson TM, Bredt DS, et al. Targeted disruption of the neuronal nitric oxide synthase gene. Cell 1993; 75(7): 1273–86

    Article  PubMed  CAS  Google Scholar 

  27. MacGregor IL, Gueller R, Watts HD, et al. The effect of acute hyperglycemia on gastric emptying in man. Gastroenterology 1976; 70(2): 190–6

    PubMed  CAS  Google Scholar 

  28. Sims MA, Hasler WL, Chey WD, et al. Hyperglycemia inhibits mechanoreceptor-mediated gastrocolonic responses and co-Ionic peristaltic reflexes in healthy humans. Gastroenterology 1995; 108(2): 350–9

    Article  PubMed  CAS  Google Scholar 

  29. Schvarcz E, Palmer M, Aman J, et al. Physiological hyperglycemia slows gastric emptying in normal subjects and patients with insulin-dependent diabetes mellitus. Gastroenterology 1997; 113(1): 60–6

    Article  PubMed  CAS  Google Scholar 

  30. Fraser R, Horowitz M, Dent J. Hyperglycaemia stimulates pyloric motility in normal subjects. Gut 1991; 32(5): 475–8

    Article  PubMed  CAS  Google Scholar 

  31. Jones KL, Russo A, Stevens JE, et al. Predictors of delayed gastric emptying in diabetes. Diabetes Care 2001; 24(7): 1264–9

    Article  PubMed  CAS  Google Scholar 

  32. Kong MF, Horowitz M. Gastric emptying in diabetes mellitus: relationship to blood-glucose control. Clin Geriatr Med 1999; 15(2): 321–38

    PubMed  CAS  Google Scholar 

  33. Melga P, Mansi C, Ciuchi E, et al. Chronic administration of levosulpiride and glycemic control in IDDM patients with gastroparesis. Diabetes Care 1997; 20(1): 55–8

    Article  PubMed  CAS  Google Scholar 

  34. Said G, Goulon-Goeau C, Slama G, et al. Severe early-onset polyneuropathy in insulin-dependent diabetes mellitus: clinical and pathological study. N Engl J Med 1992; 326(19): 1257–63

    Article  PubMed  CAS  Google Scholar 

  35. Scarpello JH, Barber DC, Hague RV, et al. Gastric emptying of solid meals in diabetics. BMJ 1976; II(6037): 671–3

    Article  Google Scholar 

  36. Buysschaert M, Moulart M, Urbain JL, et al. Impaired gastric emptying in diabetic patients with cardiac autonomie neuropathy. Diabetes Care 1987; 10(4): 448–52

    Article  PubMed  CAS  Google Scholar 

  37. Wegener M, Borsch G, Schaffstein J, et al. Gastrointestinal transit disorders in patients with insulin-treated diabetes mellitus. Dig Dis 1990; 8(1): 23–36

    Article  PubMed  CAS  Google Scholar 

  38. Koch KL, Stern RM, Vasey MW, et al. Neuroendocrine and gastric myoelectrical responses to illusory self-motion in humans. Am J Physiol 1990; 258 (2 Pt 1): E304–10

    PubMed  CAS  Google Scholar 

  39. Stoddard CJ, Smallwood RH, Duthie HL. Electrical arrhythmias in the human stomach. Gut 1981; 22(9): 705–12

    Article  PubMed  CAS  Google Scholar 

  40. Wrzos HF, Cruz A, Polavarapu R, et al. Nitric oxide synthase (NOS) expression in the myenteric plexus of streptozotocindiabetic rats. Dig Dis Sci 1997; 42(10): 2106–10

    Article  PubMed  CAS  Google Scholar 

  41. Takahashi T, Nakamura K, Itoh H, et al. Impaired expression of nitric oxide synthase in the gastric myenteric plexus of spontaneously diabetic rats. Gastroenterology 1997; 113(5): 1535–44

    Article  PubMed  CAS  Google Scholar 

  42. Watkins CC, Sawa A, Jaffrey S, et al. Insulin restores neuronal nitric oxide synthase expression and function that is lost in diabetic gastropathy. J Clin Invest 2000; 106(3): 373–84

    Article  PubMed  CAS  Google Scholar 

  43. Kusafuka T, Puri P. Altered messenger RNA expression of the neuronal nitric oxide synthase gene in infantile hypertrophic pyloric stenosis. Pediatr Surg Int 1997; 12(8): 576–9

    Article  PubMed  CAS  Google Scholar 

  44. He CL, Soffer EE, Ferris CD, et al. Loss of interstitial cells of cajal and inhibitory innervation in insulin-dependent diabetes. Gastroenterology 2001; 121(2): 427–34

    Article  PubMed  CAS  Google Scholar 

  45. Ordog T, Takayama I, Cheung WK, et al. Remodeling of networks of interstitial cells of Cajal in a murine model of diabetic gastroparesis. Diabetes 2000; 49(10): 1731–9

    Article  PubMed  CAS  Google Scholar 

  46. Hoogerwerf W, Pasricha P, Kalloo A, et al. Pain: the overlooked symptom in gastroparesis. Am J Gastroenterol 1999; 94(4): 1029–33

    Article  PubMed  CAS  Google Scholar 

  47. Holloway RH, Hongo M, Berger K, et al. Gastric distention: a mechanism for postprandial gastroesophageal reflux. Gastroenterology 1985; 89(4): 779–84

    PubMed  CAS  Google Scholar 

  48. Holloway RH, Kocyan P, Dent J. Provocation of transient lower esophageal sphincter relaxations by meals in patients with symptomatic gastroesophageal reflux. Dig Dis Sci 1991; 36(8): 1034–9

    Article  PubMed  CAS  Google Scholar 

  49. Zarich S, Waxman S, Freeman RT, et al. Effect of autonomic nervous system dysfunction on the circadian pattern of myocardial ischemia in diabetes mellitus. J Am Coll Cardiol 1994; 24(4): 956–62

    Article  PubMed  CAS  Google Scholar 

  50. Lartigue S, Bizais Y, Des Varannes SB, et al. Inter- and intrasubject variability of solid and liquid gastric emptying parameters: a scintigraphic study in healthy subjects and diabetic patients. Dig Dis Sci 1994; 39(1): 109–15

    Article  PubMed  CAS  Google Scholar 

  51. Lin HC, Hasler WL. Disorders of gastric emptying. In: Yamada T, editor. Textbook of gastroenterology. 2nd ed. Philadelphia (PA): Lippincott, 1995: 1318–46

    Google Scholar 

  52. Tougas G, Chen Y, Coates G, et al. Standardization of a simplified scintigraphic methodology for the assessment of gastric emptying in a multicenter setting. Am J Gastroenterol 2000; 95(1): 78–86

    Article  PubMed  CAS  Google Scholar 

  53. Stacher G. Diabetes and the stomach. Dig Liver Dis 2000; 32 Suppl. 3: S253–4

    Article  PubMed  Google Scholar 

  54. Bjorkman DJ, Moore JG, Klein PD, et al. 13C-bicarbonate breath test as a measure of gastric emptying. Am J Gastroenterol 1991; 86(7): 821–3

    PubMed  CAS  Google Scholar 

  55. Ghoos YF, Maes BD, Geypens BJ, et al. Measurement of gastric emptying rate of solids by means of a carbon-labeled octanoic acid breath test. Gastroenterology 1993; 104(6): 1640–7

    PubMed  CAS  Google Scholar 

  56. Maes BD, Ghoos YF, Geypens BJ, et al. Combined carbon-13-glycine/carbon-14-octanoic acid breath test to monitor gastric emptying rates of liquids and solids. J Nucl Med 1994; 35(5): 824–31

    PubMed  CAS  Google Scholar 

  57. Lee JS, Camilleri M, Zinsmeister AR, et al. A valid, accurate, office based non-radioactive test for gastric emptying of solids. Gut 2000; 46(6): 768–73

    Article  PubMed  CAS  Google Scholar 

  58. Talley NJ, Verlinden M, Geenen DJ, et al. Effects of a motilin receptor agonist (ABT-229) on upper gastrointestinal symptoms in type 1 diabetes mellitus: a randomised, double blind, placebo controlled trial. Gut 2001; 49(3): 395–401

    Article  PubMed  CAS  Google Scholar 

  59. Choi MG, Camilleri M, Burton DD, et al. Reproducibility and simplification of 13C-octanoic acid breath test for gastric emptying of solids. Am J Gastroenterol 1998; 93(1): 92–8

    Article  PubMed  CAS  Google Scholar 

  60. Stern RM, Koch KL, Stewart WR, et al. Electrogastrography: current issues in validation and methodology. Psychophysiology 1987; 24(1): 55–64

    Article  PubMed  CAS  Google Scholar 

  61. Koch KL, Stern RM, Stewart WR, et al. Gastric emptying and gastric myoelectrical activity in patients with diabetic gastroparesis: effect of long-term domperidone treatment. Am J Gastroenterol 1989; 84(9): 1069–75

    PubMed  CAS  Google Scholar 

  62. Sun WM, Smout A, Malbert C, et al. Relationship between surface electrogastrography and antropyloric pressures. Am J Physiol 1995; 268 (3 Pt 1): G424–30

    PubMed  CAS  Google Scholar 

  63. Horowitz M, Fraser RJ. Gastroparesis: diagnosis and management. Scand J Gastroenterol Suppl 1995; 213: 7–16

    PubMed  CAS  Google Scholar 

  64. Gilbey SG, Watkins PJ. Measurement by epigastric impedance of gastric emptying in diabetic autonomic neuropathy. Diabet Med 1987; 4(2): 122–6

    Article  PubMed  CAS  Google Scholar 

  65. Vaisman N, Weintrob N, Blumental A, et al. Gastric emptying in patients with type I diabetes mellitus. Ann N Y Acad Sci 1999; 873: 506–11

    Article  PubMed  CAS  Google Scholar 

  66. Gilja OH, Detmer PR, Jong JM, et al. Intragastric distribution and gastric emptying assessed by three-dimensional ultrasonography. Gastroenterology 1997; 113(1): 38–49

    Article  PubMed  CAS  Google Scholar 

  67. Pande H, Lacy B, Garuda S, et al. PET scan: a novel imaging technique to assess gastric emptying [abstract]. Am J Gastroenterol 2001; 96 Suppl. 9: S65

    Article  Google Scholar 

  68. Koch KL, Stern RM. Functional disorders of the stomach. Semin Gastrointest Dis 1996; 7(4): 185–95

    PubMed  CAS  Google Scholar 

  69. Barnett JL, Owyang C. Serum glucose concentration as a modulator of interdigestive gastric motility. Gastroenterology 1988; 94(3): 739–44

    PubMed  CAS  Google Scholar 

  70. Hasler WL, Soudah HC, Dulai G, et al. Mediation of hyperglycemia-evoked gastric slow-wave dysrhythmias by endogenous prostaglandins. Gastroenterology 1995; 108(3): 727–36

    Article  PubMed  CAS  Google Scholar 

  71. Moore JG, Datz FL, Christian PE. Exercise increases solid meal gastric emptying rates in men. Dig Dis Sci 1990; 35(4): 428–32

    Article  PubMed  CAS  Google Scholar 

  72. Cammack J, Read NW, Cann PA, et al. Effect of prolonged exercise on the passage of a solid meal through the stomach and small intestine. Gut 1982; 23(11): 957–61

    Article  PubMed  CAS  Google Scholar 

  73. Feldman M, Nixon JV. Effect of exercise on postprandial gastric secretion and emptying in humans. J Appl Physiol 1982; 53(4): 851–4

    PubMed  CAS  Google Scholar 

  74. Neufer PD, Young AJ, Sawka MN. Gastric emptying during walking and running: effects of varied exercise intensity. Eur J Appl Physiol Occup Physiol 1989; 58(4): 440–5

    Article  PubMed  CAS  Google Scholar 

  75. Rabine JC, Barnett JL. Management of the patient with gastroparesis. J Clin Gastroenterol 2001; 32(1): 11–8

    Article  PubMed  CAS  Google Scholar 

  76. Albibi R, McCallum RW. Metoclopramide: pharmacology and clinical application. Ann Intern Med 1983; 98(1): 86–95

    PubMed  CAS  Google Scholar 

  77. Ramsbottom N, Hunt JN. Studies of the effect of metoclopramide and apomorphine on gastric emptying and secretion in man. Gut 1970; 11(12): 989–93

    Article  PubMed  CAS  Google Scholar 

  78. Monkovic I, Willner D, Adam MA, et al. Substituted benzamides: potential nondopaminergic antagonists of chemotherapy. Induced nausea and emesis. J Med Chem 1988; 31(8): 1548–58

    CAS  Google Scholar 

  79. Eisner M. Gastrointestinal effects of metoclopramide in man: in vitro experiments with human smooth muscle preparations. BMJ 1968; 4(632): 679–80

    Article  PubMed  CAS  Google Scholar 

  80. Schade RR, Dugas MC, Lhotsky DM, et al. Effect of metoclopramide on gastric liquid emptying in patients with diabetic gastroparesis. Dig Dis Sci 1985; 30(1): 10–5

    Article  PubMed  CAS  Google Scholar 

  81. McCallum RW. Clinical pharmacology forum: motility agents and the gastrointestinal tract. Am J Med Sci 1996; 312(1): 19–26

    Article  PubMed  CAS  Google Scholar 

  82. Malagelada JR. Gastric emptying disorders: clinical significance and treatment. Drugs 1982; 24(5): 353–9

    Article  PubMed  CAS  Google Scholar 

  83. Miller LG, Jankovic J. Metoclopramide-induced movement disorders: clinical findings with a review of the literature. Arch Intern Med 1989; 149(11): 2486–92

    Article  PubMed  CAS  Google Scholar 

  84. Avorn J, Gurwitz JH, Bohn RL, et al. Increased incidence of levodopa therapy following metoclopramide use. JAMA 1995; 274(22): 1780–2

    Article  PubMed  CAS  Google Scholar 

  85. Ganzini L, Casey DE, Hoffman WF, et al. The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders. Arch Intern Med 1993; 153(12): 1469–75

    Article  PubMed  CAS  Google Scholar 

  86. Minami H, McCallum RW. The physiology and pathophysiology of gastric emptying in humans. Gastroenterology 1984; 86(6): 1592–610

    PubMed  CAS  Google Scholar 

  87. McHugh S, Lico S, Diamant NE. Cisapride vs metoclopramide: an acute study in diabetic gastroparesis. Dig Dis Sci 1992; 37(7): 997–1001

    Article  PubMed  CAS  Google Scholar 

  88. Pandolfino JE, Howden CW, Kahrilas PJ. Motility-modifying agents and management of disorders of gastrointestinal motility. Gastroenterology 2000; 118 (2 Suppl. 1): S32–47

    Article  PubMed  CAS  Google Scholar 

  89. Chen JD, Lin ZY, Edmunds III MC, et al. Effects of octreotide and erythromycin on gastric myoelectrical and motor activities in patients with gastroparesis. Dig Dis Sci 1998; 43(1): 80–9

    Article  PubMed  CAS  Google Scholar 

  90. Richards RD, Davenport K, McCallum RW. The treatment of idiopathic and diabetic gastroparesis with acute intravenous and chronic oral erythromycin. Am J Gastroenterol 1993; 88(2): 203–7

    PubMed  CAS  Google Scholar 

  91. Saloranta P, Roos L, Elonen E, et al. Erythromycin ethylsuccinate, base and acistrate in the treatment of upper respiratory tract infection: two comparative studies of tolerability. J Antimicrob Chemother 1989; 24(3): 455–62

    Article  PubMed  CAS  Google Scholar 

  92. Hasler WL. The brute force approach to electrical stimulation of gastric emptying: a future treatment for refractory gastroparesis? Gastroenterology 2000; 118(2): 433–6

    Article  PubMed  CAS  Google Scholar 

  93. Orban Z, MacDonald LL, Peters MA, et al. Erythromycin-induced cardiac toxicity. Am J Cardiol 1995; 75(12): 859–61

    Article  PubMed  CAS  Google Scholar 

  94. Sturm A, Holtmann G, Goebell H. Treatment of patients with gastroparesis: a meta-analysis of prokinetics [abstract]. Gastroenterology 1997; 112: A833

    Google Scholar 

  95. Kendall BJ, Chakravarti A, Kendall E, et al. The effect of intravenous erythromycin on solid meal gastric emptying in patients with chronic symptomatic post-vagotomy-antrectomy gastroparesis. Aliment Pharmacol Ther 1997; 11(2): 381–5

    Article  PubMed  CAS  Google Scholar 

  96. Annese V, Lombardi G, Frusciante V, et al. Cisapride and erythromycin prokinetic effects in gastroparesis due to type 1 (insulin-dependent) diabetes mellitus. Aliment Pharmacol Ther 1997; 11(3): 599–603

    Article  PubMed  CAS  Google Scholar 

  97. Janssens J, Peeters TL, Vantrappen G, et al. Improvement of gastric emptying in diabetic gastroparesis by erythromycin: preliminary studies. N Engl J Med 1990; 322(15): 1028–31

    Article  PubMed  CAS  Google Scholar 

  98. Ueno N, Inui A, Asakawa A, et al. Erythromycin improves glycaemic control in patients with type II diabetes mellitus. Diabetologia 2000; 43(4): 411–5

    Article  PubMed  CAS  Google Scholar 

  99. Hasler WL. Disorders of gastric emptying. In: Yamada T, editor. Textbook of gastroenterology. Philadelphia (PA): Lippincott,Williams and Wilkins, 1999: 1341–69

    Google Scholar 

  100. Matsunaga H, Tanaka M, Naritomi G, et al. Effect of leucine 13-motilin (KW5139) on early gastric stasis after pylorus-preserving pancreatoduodenectomy. Ann Surg 1998; 227(4): 507–12

    Article  PubMed  CAS  Google Scholar 

  101. McCallum RW. Cisapride: a new class of prokinetic agent. The ACG Committee on FDA-related matters. American College of Gastroenterology. Am J Gastroenterol 1991; 86(2): 135–49

    CAS  Google Scholar 

  102. Fraser RJ, Horowitz M, Maddox AF, et al. Postprandial antropyloroduodenal motility and gastric emptying in gastroparesis: effects of cisapride. Gut 1994; 35(2): 172–8

    Article  PubMed  CAS  Google Scholar 

  103. Barone JA, Jessen LM, Colaizzi JL, et al. Cisapride: a gastrointestinal prokinetic drug. Ann Pharmacother 1994; 28(4): 488–500

    PubMed  CAS  Google Scholar 

  104. McCallum RW, Prakash C, Campoli-Richards DM, et al. Cisapride: a preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use as a prokinetic agent in gastrointestinal motility disorders. Drugs 1988; 36(6): 652–81

    Article  PubMed  CAS  Google Scholar 

  105. De Ponti F, Malagelada JR. Functional gut disorders: from motility to sensitivity disorders. A review of current and investigational drugs for their management. Pharmacol Ther 1998; 80(1): 49–88

    Google Scholar 

  106. Horowitz M, Maddox A, Harding PE, et al. Effect of cisapride on gastric and esophageal emptying in insulin-dependent diabetes mellitus. Gastroenterology 1987; 92(6): 1899–907

    PubMed  CAS  Google Scholar 

  107. Horowitz M, Roberts AP. Long-term efficacy of cisapride in diabetic gastroparesis. Am J Med 1990; 88(2): 195–6

    Article  PubMed  CAS  Google Scholar 

  108. Abell TL, Camilleri M, DiMagno EP, et al. Long-term efficacy of oral cisapride in symptomatic upper gut dysmotility. Dig Dis Sci 1991; 36(5): 616–20

    Article  PubMed  CAS  Google Scholar 

  109. Dworkin BM, Rosenthal WS, Casellas AR, et al. Open label study of long-term effectiveness of cisapride in patients with idiopathic gastroparesis. Dig Dis Sci 1994; 39(7): 1395–8

    Article  PubMed  CAS  Google Scholar 

  110. Kawagishi T, Nishizawa Y, Okuno Y, et al. Effect of cisapride on gastric emptying of indigestible solids and plasma motilin concentration in diabetic autonomie neuropathy. Am J Gastroenterol 1993; 88(6): 933–8

    PubMed  CAS  Google Scholar 

  111. Camilleri M, Malagelada JR, Abell TL, et al. Effect of six weeks of treatment with cisapride in gastroparesis and intestinal pseudoobstruction. Gastroenterology 1989; 96(3): 704–12

    PubMed  CAS  Google Scholar 

  112. Richards RD, Valenzuela GA, Davenport KG, et al. Objective and subjective results of a randomized, double-blind, placebo-controlled trial using cisapride to treat gastroparesis. Dig Dis Sci 1993; 38(5): 811–6

    Article  PubMed  CAS  Google Scholar 

  113. Prakash A, Wagstaff AJ. Domperidone: a review of its use in diabetic gastropathy. Drugs 1998; 56(3): 429–45

    Article  PubMed  CAS  Google Scholar 

  114. Kozarek R. Domperidone for symptomatic management of diabetic gastroparesis in metoclopramide treatment failures. Adv Ther 1990 Mar–Apr; 7: 61–68

    Google Scholar 

  115. Stern WR. Omeprazole and domperidone. Summary of the 34th meeting of the Food and Drug Administration Gastrointestinal Drugs Advisory Committee. 1989 Mar 15–16; Washington, DC. Am J Gastroenterol 1989; 84(11): 1351–5

    CAS  Google Scholar 

  116. Horowitz M, Harding PE, Chatterton BE, et al. Acute and chronic effects of domperidone on gastric emptying in diabetic autonomie neuropathy. Dig Dis Sci 1985; 30(1): 1–9

    Article  PubMed  CAS  Google Scholar 

  117. Silvers D, Kipnes M, Broadstone V, et al. Domperidone in the management of symptoms of diabetic gastroparesis: efficacy, tolerability, and quality-of-life outcomes in a multicenter controlled trial. DOM-USA-5 Study Group. Clin Ther 1998; 20(3): 438–53

    CAS  Google Scholar 

  118. Webb WW, Fogel RP. Gastroparesis: current management. Compr Ther 1995; 21(12): 741–5

    PubMed  CAS  Google Scholar 

  119. Fox S, Behar J. Pathogenesis of diabetic gastroparesis: a pharmacologic study. Gastroenterology 1980; 78(4): 757–63

    PubMed  CAS  Google Scholar 

  120. Malagelada JR, Rees WD, Mazzotta LJ, et al. Gastric motor abnormalities in diabetic and postvagotomy gastroparesis: effect of metoclopramide and bethanechol. Gastroenterology 1980; 78(2): 286–93

    PubMed  CAS  Google Scholar 

  121. McCallum RW, Fink SM, Lerner E, et al. Effects of metoclopramide and bethanechol on delayed gastric emptying present in gastroesophageal reflux patients. Gastroenterology 1983; 84(6): 1573–7

    PubMed  CAS  Google Scholar 

  122. Parkman HP, Trate DM, Knight LC, et al. Cholinergic effects on human gastric motility. Gut 1999; 45(3): 346–54

    Article  PubMed  CAS  Google Scholar 

  123. Kim CH, Nelson DK. Venting percutaneous gastrostomy in the treatment of refractory idiopathic gastroparesis. Gastrointest Endosc 1998; 47(1): 67–70

    Article  PubMed  CAS  Google Scholar 

  124. Mathus-Vliegen LM, Koning H. Percutaneous endoscopie gastrostomy and gastrojejunostomy: a critical reappraisal of patient selection, tube function and the feasibility of nutritional support during extended follow-up. Gastrointest Endosc 1999; 50(6): 746–54

    Article  PubMed  CAS  Google Scholar 

  125. Fontana RJ, Barnett JL. Jejunostomy tube placement in refractory diabetic gastroparesis: a retrospective review. Am J Gastroenterol 1996; 91(10): 2174–8

    PubMed  CAS  Google Scholar 

  126. Eckhauser FE, Knol JA, Raper SA, et al. Completion gastrectomy for postsurgical gastroparesis syndrome: preliminary results with 15 patients. Ann Surg 1988; 208(3): 345–53

    Article  PubMed  CAS  Google Scholar 

  127. Reardon TM, Schnell GA, Smith OJ, et al. Surgical therapy of diabetic gastroparesis. J Clin Gastroenterol 1989; 11(2): 204–7

    Article  PubMed  CAS  Google Scholar 

  128. Bell DS, Ovalle F. Gastroparesis cured by gastrectomy. Diabetes Care 1999; 22(6): 1000–1

    Article  PubMed  CAS  Google Scholar 

  129. Hocking MP, Vogel SB, Sninsky CA. Human gastric myoelectric activity and gastric emptying following gastric surgery and with pacing. Gastroenterology 1992; 103(6): 1811–6

    PubMed  CAS  Google Scholar 

  130. Eagon JC, Kelly KA. Effect of electrical stimulation on gastric electrical activity, motility and emptying. Neurogastroenterol Motil 1995; 7(1): 39–45

    Article  PubMed  CAS  Google Scholar 

  131. McCallum RW, Chen JD, Lin Z, et al. Gastric pacing improves emptying and symptoms in patients with gastroparesis. Gastroenterology 1998; 114(3): 456–61

    Article  PubMed  CAS  Google Scholar 

  132. Tack J. The influence of gastric electrical stimulation on proximal gastric motor and sensory function in severe idiopathic gastroparesis [abstract]. Gastroenterology 1999 Apr; 16: A1090

    Google Scholar 

  133. Lacy BE, Zayat EN, Crowell MD, et al. Botulism toxin for the treatment of gastroparesis [abstract]. Gastroenterology 2000; 118: A624

    Article  Google Scholar 

  134. Novick J, Miner P, Krause R, et al. A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2002; 16(11): 1877–88

    Article  PubMed  CAS  Google Scholar 

  135. Degen L, Matzinger D, Merz M, et al. Tegaserod, a 5-HT4 receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects. Aliment Pharmacol Ther 2001; 15(11): 1745–51

    Article  PubMed  CAS  Google Scholar 

  136. Mansi C, Savarino V, Vigneri S, et al. Gastrokinetic effects of levosulpiride in dyspeptic patients with diabetic gastroparesis. Am J Gastroenterol 1995; 90(11): 1989–93

    PubMed  CAS  Google Scholar 

  137. Mansi C, Borro P, Giacomini M, et al. Comparative effects of levosulpiride and cisapride on gastric emptying and symptoms in patients with functional dyspepsia and gastroparesis. Aliment Pharmacol Ther 2000; 14(5): 561–9

    Article  PubMed  CAS  Google Scholar 

  138. Schwizer W, Borovicka J, Kunz P, et al. Role of cholecystokinin in the regulation of liquid gastric emptying and gastric motility in humans: studies with the CCK antagonist loxiglumide. Gut 1997; 41(4): 500–4

    Article  PubMed  CAS  Google Scholar 

  139. Jones KL, Wishart JM, Berry MK, et al. Effects of fedotozine on gastric emptying and upper gastrointestinal symptoms in diabetic gastroparesis. Aliment Pharmacol Ther 2000; 14(7): 937–43

    Article  PubMed  CAS  Google Scholar 

  140. Coffin B, Bouhassira D, Chollet R, et al. Effect of the kappa agonist fedotozine on perception of gastric distension in healthy humans. Aliment Pharmacol Ther 1996; 10(6): 919–25

    Article  PubMed  CAS  Google Scholar 

  141. Delvaux M, Louvel D, Lagier E, et al. The kappa agonist fedotozine relieves hypersensitivity to colonic distention in patients with irritable bowel syndrome. Gastroenterology 1999; 116(1): 38–45

    Article  PubMed  CAS  Google Scholar 

  142. Read NW, Abitbol JL, Bardhan KD, et al. Efficacy and safety of the peripheral kappa agonist fedotozine versus placebo in the treatment of functional dyspepsia. Gut 1997; 41(5): 664–8

    Article  PubMed  CAS  Google Scholar 

  143. Aktas A, Caner B, Ozturk F, et al. The effect of trimebutine maleate on gastric emptying in patients with non-ulcer dyspepsia. Ann Nucl Med 1999; 13(4): 231–4

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

Supported by a grant from the Juvenile Diabetes Research Foundation (JDRF 1-2002-46) [to CDF] and an NIH Training in Gastroenterology grant (2T32DK07673) [to DSS]. Christopher D. Ferris serves as a consultant for Eli Lilly ICOS LLC and has an interest in a licensing agreement related to potential uses of phosphodiesterase inhibitors in intestinal disorders.

Author information

Authors and Affiliations

  1. Department of Medicine, Division of Gastroenterology, Vanderbilt University Medical Center, 1161 21st Avenue South, Medical Center North, C2104, Nashville, Tennessee, 37232, USA

    D. Scott Smith &  Christopher D. Ferris

  2. Nashville Veterans Affairs Hospital, Nashville, Tennessee, USA

    D. Scott Smith &  Christopher D. Ferris

  3. Department of Cell and Developmental Biology, Vanderbilt University Medical Center, 1161 21st Avenue South, Medical Center North, C2104, Nashville, Tennessee, 37232, USA

    Christopher D. Ferris

Authors
  1. D. Scott Smith
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christopher D. Ferris
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christopher D. Ferris.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Smith, D.S., Ferris, C.D. Current Concepts in Diabetic Gastroparesis. Drugs 63, 1339–1358 (2003). https://doi.org/10.2165/00003495-200363130-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200363130-00002

Keywords

Search

Navigation